Division of Rheumatology, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden.
Department of Rheumatology, Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, 100029, China.
Best Pract Res Clin Rheumatol. 2022 Jun;36(2):101767. doi: 10.1016/j.berh.2022.101767. Epub 2022 Jul 7.
Idiopathic inflammatory myopathies (IIM) are heterogeneous autoimmune diseases. There are distinct subgroups, including antisynthetase syndrome, dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and sporadic inclusion body myositis. In patients with IIM, autoantibodies are present in up to 80% of the patients. These autoantibodies are often characterized as myositis-specific autoantibodies (MSA) or myositis-associated autoantibodies (MAA). The recognition of the importance of autoantibodies, especially MSA, is increasing in recent years. In this chapter, we provide an overview of the MSAs, including some new autoantibodies of interest as they target mainly muscle-specific autoantigen, in clinical classification, the measurement of the disease activity, and a possible role in the pathogenesis in the patients with IIM.
特发性炎性肌病（IIM）是一组异质性自身免疫性疾病。其存在多种亚型，包括抗合成酶综合征、皮肌炎、多发性肌炎、免疫介导的坏死性肌病和散发性包涵体肌炎。在 IIM 患者中，高达 80%的患者存在自身抗体。这些自身抗体通常被称为肌炎特异性自身抗体（MSA）或肌炎相关自身抗体（MAA）。近年来，人们越来越认识到自身抗体的重要性，尤其是 MSA。在本章中，我们将概述 MSA，包括一些新的有研究价值的自身抗体，这些自身抗体主要针对肌肉特异性自身抗原，在临床分类、疾病活动的评估以及在 IIM 患者发病机制中的可能作用。
